Achieve Life Sciences, Inc. ACHV
Set alert
6.66 USD -0.17 -2.49%
As of Nov 2, 10:26 AM ET
6.64 Day range 6.89
2.62 52-week range 8.64
- YTD
- +34.00%
- 1 year
- +30.08%
- Open
- 6.89
- Prev close
- 6.83
- Mkt cap
- 684.60M
- Vol
- 314.47K
- Avg vol
- 1.45M
- EPS
- -1.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.64
- High
- 6.89
- Forward P/E
- -3.30
- Beta
- 1.58
- Short ratio
- 23.98
- Inst. own
- 59.60%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.53
- 200-d avg
- 4.66
- 1y target
- 16.44
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.36; estimate -0.26; surprise -38.46%
- Nov 14, 2024Rating: Rodman & Renshaw · — → Buy
Signals (81)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| RSI: Overbought | Apr 16, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| SMA: Bullish | Feb 26, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| SMA: Bearish | Jan 27, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| RSI: Overbought | Jan 16, 2026 | 9 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 30, 2025 | 10 months ago |
| SMA: Bearish | Dec 16, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 3, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 5, 2025 | 12 months ago |
| RSI: Overbought | Oct 29, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 17, 2025 | 1 year ago |
| RSI: Overbought | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 23, 2025 | 1 year ago |
| SMA: Bearish | Sep 17, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 17, 2025 | 1 year ago |
| SMA: Bullish | Sep 16, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 9, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 9, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Aug 29, 2025 | 1 year ago |
| SMA: Bullish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 26, 2025 | 1 year ago |
| SMA: Bullish | Aug 25, 2025 | 1 year ago |
| RSI: Overbought | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 21, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 12, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 26, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| RSI: Overbought | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| SMA: Bearish | May 14, 2025 | 1 year ago |
| SMA: Bullish | May 13, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | May 5, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 12, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 7, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 28, 2025 | 1 year ago |
| RSI: Oversold | Jan 16, 2025 | 1 year ago |
| RSI: Oversold | Jan 14, 2025 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 19, 2024 | 1 year ago |
Key statistics
- Market cap
- 130.34M
- Enterprise value
- 93.83M
- Trailing P/E
- 0.00
- Forward P/E
- -3.30
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.16
- EPS (TTM)
- -1.12
- Beta
- 1.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -14.94M
- Total cash
- 42.91M
- Total debt
- 9.85M
- Return on equity
- -186.03%
- Shares outstanding
- 34.39M
- Short % of float
- 10.85%
- 50-day average
- 4.53
- 200-day average
- 4.66
Analyst view
Consensus: none
Price target (mean) 16.44 +146.9% upside
Now 6.66
- Target (low)
- 10.00
- Target (mean)
- 16.44
- Target (high)
- 30.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.36.
Financials — quick view
ACHV Revenue — quarterly 0
ACHV Net income — quarterly -74.77M
ACHV EPS — quarterly -0.80
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.26 | -0.36 | -0.10 | -38.46% |
| Aug 13, 2024 | Jun 1, 2024 | -0.22 | -0.25 | -0.03 | -13.64% |
| May 9, 2024 | Mar 1, 2024 | -0.24 | -0.26 | -0.02 | -8.33% |
| Mar 28, 2024 | Dec 1, 2023 | -0.32 | -0.26 | +0.06 | +18.75% |
| Nov 9, 2023 | Sep 1, 2023 | -0.34 | -0.34 | 0.00 | 0.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.41 | -0.43 | -0.02 | -4.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
| Aug 15, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 13, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 17, 2024 | JonesTrading | init | — | Buy |
| Apr 1, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Mar 5, 2024 | Lake Street | main | Buy | Buy |
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- achievelifesciences.com
News
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences (NASDAQ:ACHV) Shares Gap Up – Here’s What Happened
- Achieve Life Sciences Appoints Benjamin Halladay CFO, Effective Oct. 5
- Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
- Stifel Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $18
- Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
- Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade)
Your note
Sign in to keep a note on ACHV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 10, 2019 | 0 |
| BENCICH JOHN A | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 17, 2020 | 141 |
| JACOBS CINDY A | Officer | Conversion of Exercise of derivative security | Aug 17, 2020 | 176 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Resources, Inc. | 11.26% | 3,871,349 | 14.67M | Sep 29, 2024 |
| Propel Bio Management, LLC | 7.13% | 2,453,092 | 9.30M | Sep 29, 2024 |
| Blackrock Inc. | 6.02% | 2,071,132 | 7.85M | Sep 29, 2024 |
| Vanguard Group Inc | 5.64% | 1,940,388 | 7.35M | Sep 29, 2024 |
| Sofinnova Investments, Inc. | 4.40% | 1,514,032 | 5.74M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.18% | 749,109 | 2.84M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 6.34% | 2,181,025 | 8.27M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.99% | 1,027,821 | 3.90M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.42% | 831,633 | 3.15M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.83% | 629,867 | 2.39M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.01% | 347,964 | 1.32M | Aug 30, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 0.63% | 217,845 | 825.63K | Sep 29, 2024 |